BDIXF
BIOLIDICS LIMITED
stock OTC

Biolidics Ltd. operates as a medical technology company. It focuses on the development of cell enrichment systems which, when combined with other analytical tests, have applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring. The firm has developed and commercialised a fully automated IVD medical device ClearCell FX1, which allows users of the system to perform liquid biopsies to test for the presence of cancer cells. It operates through the following segments: Technical and Product Development, Global Commercial Channel Management, and Corporate. The Technical and Product Development segment involves identifying and assessing collaboration partners and their technology, provision of technical expertise in revenue generating collaboration projects, and product innovation and improvement. The Global Commercial Channel Management segment deals with the management of global distributorship network and direct customers. The Corporate segment refers to the corporate functions in supporting the operations of the group. The company was founded by Johnson Chen on July 19, 2009 and is headquartered in Singapore.